First dual inhibitors of human topoisomerase IIα and Hsp90 C-terminal domain inhibit the growth of Ewing sarcoma in vitro and in vivo.

导出 LinkOut

翻译打印收藏纠错

作者： Jaka,Dernovšek ^[1] ; Dunja,Urbančič ^[1] ; Živa,Zajec ^[1] ; Caterina,Sturtzel ^[2] ; Sarah,Grissenberger ^[2] ; Andrea,Wenninger-Weinzierl ^[2] ; Marius,Gedgaudas ^[3] ; Asta,Zubrienė ^[3] ; Tjaša,Goričan ^[4] ; Simona,Golič Grdadolnik ^[4] ; Žiga,Skok ^[1] ; Janez,Ilaš ^[1] ; Martin,Distel ^[2] ; Nace,Zidar ^[5] ; Tihomir,Tomašič ^[6]

作者单位： Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. ^[1] St. Anna Children's Cancer Research Institute, Zimmermannplatz 10, 1090 Vienna, Austria. ^[2] Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, LT-10257 Vilnius, Lithuania. ^[3] Laboratory for Molecular Structural Dynamics, Theory Department, National Institute of Chemistry, Hajdrihova 19, 1001 Ljubljana, Slovenia. ^[4] Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address: nace.zidar@ffa.uni-lj.si. ^[5] Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. Electronic address: tihomir.tomasic@ffa.uni-lj.si. ^[6]

关键词 Cancer Ewing sarcoma Hsp90 Inhibitor Topoisomerase IIα Zebrafish